Drug Trial Radar · NCT02113982
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Last checked: Nov 20, 2026Latest source record: Aug 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
138
Actual
Start
Sep 2014
Primary completion
Feb 1, 2020
Study completion Mar 12, 2020
Sponsor
- Lead sponsor
- Stemline Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- The Leukemia and Lymphoma Society
- First posted
- Apr 15, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 4-stage, non-randomized, open-label, dose escalation and expansion, multicenter study. A cycle of therapy is 21 days. Stage 1 was a dose-escalation stage. During Stages 2-4, patients are treated at the MTD or maximum tested dose at which multiple DLTs are not observed during Stage 1.
Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Acute Myeloid Leukemia (AML)
Interventions
TagraxofuspDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTD (Stage 1)Time frame: 21-day period after the first dose (cycle 1)
- CR Rate in First-line BPDCN (Stage 3, Pivotal Cohort)Time frame: at pre-defined treatment cycle intervals from randomization up to disease progression, up to 3.5 years
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
H. Lee Moffiitt Cancer Center & Research Institute
Tampa, Florida
Dana Farber Cancer Institute
Boston, Massachusetts
Roswell Park Cancer Institute
Buffalo, New York
Columbia University Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Ohio State University
Columbus, Ohio
University of Pittsburgh Medical Center Presbyterian Shady Side
Pittsburgh, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.